Nature Communications (Aug 2022)
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
- Daniel J. Renouf,
- Jonathan M. Loree,
- Jennifer J. Knox,
- James T. Topham,
- Petr Kavan,
- Derek Jonker,
- Stephen Welch,
- Felix Couture,
- Frederic Lemay,
- Mustapha Tehfe,
- Mohammed Harb,
- Nathalie Aucoin,
- Yoo-Joung Ko,
- Patricia A. Tang,
- Ravi Ramjeesingh,
- Brandon M. Meyers,
- Christina A. Kim,
- Pan Du,
- Shidong Jia,
- David F. Schaeffer,
- Sharlene Gill,
- Dongsheng Tu,
- Chris J O’Callaghan
Affiliations
- Daniel J. Renouf
- Pancreas Centre BC
- Jonathan M. Loree
- Division of Medical Oncology, BC Cancer
- Jennifer J. Knox
- Princess Margaret Cancer Centre, UHN, University of Toronto
- James T. Topham
- Pancreas Centre BC
- Petr Kavan
- Department of Medicine and Oncology, Sir Mortimer B. Davis Jewish General Hospital, Segal Cancer Centre, McGill University
- Derek Jonker
- The Ottawa Hospital, University of Ottawa
- Stephen Welch
- London Regional Cancer Program
- Felix Couture
- CHU de Quebec Research Centre and Faculty of Medicine, Laval University
- Frederic Lemay
- Faculty of Medicine and Health Sciences, University of Sherbrooke
- Mustapha Tehfe
- Hematology and Medical Oncology Division, Centre Hospitalier Universitaire de Montreal, University of Montreal
- Mohammed Harb
- The Moncton City Hospital
- Nathalie Aucoin
- Hopital Cite-de-la-Sante
- Yoo-Joung Ko
- Department of Medicine, Sunnybrook Odette Cancer Centre
- Patricia A. Tang
- University of Calgary
- Ravi Ramjeesingh
- Nova Scotia Cancer Centre and Dalhousie University
- Brandon M. Meyers
- Juravinski Cancer Centre
- Christina A. Kim
- CancerCare Manitoba
- Pan Du
- Predicine, Inc.
- Shidong Jia
- Predicine, Inc.
- David F. Schaeffer
- Pancreas Centre BC
- Sharlene Gill
- Division of Medical Oncology, BC Cancer
- Dongsheng Tu
- Canadian Cancer Trials Group, Queen’s University
- Chris J O’Callaghan
- Canadian Cancer Trials Group, Queen’s University
- DOI
- https://doi.org/10.1038/s41467-022-32591-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 8
Abstract
Metastatic pancreatic ductal adenocarcinoma (mPDAC) has limited therapeutic options and is associated with a poor prognosis. Here the authors report the results of a randomized phase II trial showing that combining checkpoint inhibitors (durvalumab and tremelimumab) with chemotherapy (gemcitabine and nab-paclitaxel) does not improve survival compared to chemotherapy alone in patients with mPDAC.
